MYGN Q4 2018 Earnings — Myriad Genetics, Inc. Revenue & Financial Results | Market Cap Arena

MYGNMyriad Genetics, Inc.

$454M

Q4 2018 Earnings

Healthcare Medical - Diagnostics & Research

Income Statement

Revenue

$217M+11.8% YoY

Gross Profit

$165M76.0% margin

Operating Income

$6M2.8% margin

Net Income

$3M1.2% margin

EPS (Diluted)

$0.03

QoQ Revenue Growth

+7.2%

Cash Flow

Operating Cash Flow

$38M

Free Cash Flow

$35M

Stock-Based Comp.

$8M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$493M

Stockholders' Equity

$1.1B

Cash & Equivalents

$91M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$217M	$194M	+11.8%
Gross Profit	$165M	$150M	+10.1%
Operating Income	$6M	$4M	+38.6%
Net Income	$3M	$32M	-91.9%

Revenue Segments

Diagnostics

$203M94%

All Other Segments

$14M6%

Geographic Segments

UNITED STATES

$206M95%

Non Us

$11M5%